StemCells Inc. (Nasdaq: STEM) reported positive interim data from a PhaseI/II clinical trial of its age-related macular degeneration treatment HuCNS-SC sending the stock price soaring 32 cents to $1.89.
Upbeat data from StemCells
June 19, 2014 at 12:52 PM EDT
